Gilead Sciences Overview

  • Founded
  • 1987

Founded
  • Status
  • Public

  • Employees
  • 14,400

Employees
  • Stock Symbol
  • GILD

Stock Symbol
  • Investments
  • 58

  • Share Price
  • $62.83

  • (As of Monday Closing)

Gilead Sciences General Information

Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Contact Information

Website
www.gilead.com
Formerly Known As
Oligogen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gilead Sciences Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$62.83 $63.08 $57.16 - $74.12 $79.1B 1.25B 8.22M $3.59

Gilead Sciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 94,826,535 113,029,788 78,371,550 84,073,162
Revenue 27,472,000 27,305,000 24,689,000 22,449,000
EBITDA 8,946,000 11,329,000 4,133,000 7,559,000
Net Income 4,515,000 6,225,000 123,000 5,386,000
Total Assets 63,080,000 67,952,000 68,407,000 61,627,000
Total Debt 26,208,000 26,695,000 31,402,000 24,593,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gilead Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portf
Pharmaceuticals
Foster City, CA
14,400 As of 2021
00.000
000000000 00.000

000000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori
000000000000000
Basel, Switzerland
000000 As of 0000
000000000000

000 00

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000 000000000
Indianapolis, IN
00000 As of 0000
000000 - 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gilead Sciences Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland 000000 000000000000
000 00000 Corporation Indianapolis, IN 00000 000000 - 000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 0&0
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000000-00000 0000 Corporation New York, NY 00000 00000 000000000 00000
You’re viewing 5 of 23 competitors. Get the full list »

Gilead Sciences Patents

Gilead Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210380561-A1 Lpa receptor antagonists and uses thereof Pending 03-Jun-2020 0000000000
US-20210355140-A1 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Pending 06-May-2020 0000000000
US-20210330685-A1 Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs Pending 06-Apr-2020 000000000
US-20210309637-A1 Solid forms of a cot inhibitor compound Pending 30-Mar-2020 0000000000
US-20210309689-A1 Methods of preparing 1'-cyano nucleosides Pending 12-Mar-2020 C07H19/23
To view Gilead Sciences’s complete patent history, request access »

Gilead Sciences Executive Team (56)

Name Title Board Seat Contact Info
Daniel O'Day Chief Executive Officer, Chairman of the Board & Director
Andrew Dickinson Chief Financial Officer, Finance & Executive Vice President
Wim Eeraerts General Manager - Belgium & Luxemburg
Diane Wilfong Chief Accounting Officer, Accounting & Controller, Finance
Jeremy O'Hanlon Director, Corporate Development
You’re viewing 5 of 56 executive team members. Get the full list »

Gilead Sciences Board Members (23)

Name Representing Role Since
Anthony Welters JD Self Board Member 000 0000
Daniel O'Day Gilead Sciences Chief Executive Officer, Chairman of the Board & Director 000 0000
Harish Manwani Self Board Member 000 0000
Jacqueline Barton Gilead Sciences Board Member 000 0000
Javier Rodriguez Self Board Member 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Gilead Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gilead Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Investments & Acquisitions (58)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 23-May-2022 0000 00000 000 Drug Discovery
00000000 05-May-2022 00000 0000 0000 Other Healthcare Technology Systems 0000 0000
0000000 26-Jan-2022 00000 0000 0000 Biotechnology 0000 0000
000000 000000 27-Dec-2021 0000 0000 Biotechnology
Gritstone bio 17-Sep-2021 PIPE 0000 Biotechnology
You’re viewing 5 of 58 investments and acquisitions. Get the full list »

Gilead Sciences Subsidiaries (3)

Company Name Industry Location Founded
Kite Pharma Biotechnology Santa Monica, CA 2009
000000 Pharmaceuticals Westminster, CO 0000
000000000000 Drug Discovery Morris Plains, NJ 0000
To view Gilead Sciences’s complete subsidiaries history, request access »

Gilead Sciences Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 10-Aug-2021 0000 00000 Completed
  • 18 buyers
000000000 17-Mar-2021 00000 00000 00 00000 Completed
  • 8 buyers
00000 000000000000 17-Aug-2020 00000 00000 00 0000 Completed
  • 4 buyers
000000000 00000000 01-Mar-2019 00000 00000 00 00000 Completed
  • 21 buyers
Hookipa Pharma 11-Dec-2017 Later Stage VC 000.00 Completed
  • 9 buyers
You’re viewing 5 of 8 exits. Get the full list »